Development and Preliminary Validation of the PrEP Empowerment Scale
- PMID: 37166688
- PMCID: PMC10592504
- DOI: 10.1007/s10461-023-04078-0
Development and Preliminary Validation of the PrEP Empowerment Scale
Abstract
Informed by the Health Care Empowerment Model, a measure of PrEP Empowerment was developed and assessed for preliminary reliability and validity. Participants (N = 100) were invited to complete a survey during regular clinic visits. A subset (n = 84) volunteered to provide blood samples to assess plasma tenofovir (TFV) levels for recent PrEP adherence. A five-factor measure explained 70% of the total variance. Associations with internalized PrEP stigma, PrEP adherence self-efficacy, and plasma TFV were assessed. Results supported the multidimensional nature of PrEP Empowerment and reliability and validity. Additional research is needed in populations with varying PrEP experience and greater gender and ethnic representation.
Basado en el modelo de empoderamiento de atención médica, se desarrolló y evaluó una medida de empoderamiento de la PrEP para determinar su confiabilidad y validez preliminares. Se invitó a los participantes (N = 100) a completar una encuesta durante las visitas regulares a la clínica. Un subconjunto (n = 84) se ofreció como voluntario para proporcionar muestras de sangre para evaluar los niveles de tenofovir (TFV) en plasma para la adherencia reciente a la PrEP. Una medida de cinco factores explicó el 70% de la varianza total. Se evaluaron las asociaciones con el estigma internalizado de la PrEP, la autoeficacia de la PrEP y el TFV plasmático. Los resultados respaldaron la naturaleza multidimensional de PrEP Empowerment y la confiabilidad y validez. Se necesita investigación adicional en poblaciones con diferentes experiencias de PrEP y una mayor representación étnica y de género.
Keywords: Adherence; Empowerment; Measure development; PrEP; Self-efficacy.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Similar articles
-
The Relationship Between HIV Pre-exposure Prophylaxis Stigma and Treatment Adherence Among Current HIV Pre-exposure Prophylaxis Users in the Southeastern U.S.AIDS Behav. 2023 May;27(5):1478-1485. doi: 10.1007/s10461-022-03883-3. Epub 2022 Oct 8. AIDS Behav. 2023. PMID: 36209179
-
Perspectives on the utility and interest in a point-of-care urine tenofovir test for adherence to HIV pre-exposure prophylaxis and antiretroviral therapy: an exploratory qualitative assessment among U.S. clients and providers.AIDS Res Ther. 2020 Aug 6;17(1):50. doi: 10.1186/s12981-020-00308-w. AIDS Res Ther. 2020. PMID: 32762713 Free PMC article.
-
Determinants of adherence to daily PrEP measured as intracellular tenofovir diphosphate concentrations over 24 months of follow-up among men who have sex with men.Sex Transm Infect. 2023 Aug;99(5):303-310. doi: 10.1136/sextrans-2022-055499. Epub 2022 Sep 5. Sex Transm Infect. 2023. PMID: 37258273 Free PMC article.
-
The effectiveness of tenofovir-based pre-exposure prophylaxis for prevention of HIV acquisition among sub-Saharan African women at high risk: a systematic review.Pan Afr Med J. 2021 Mar 26;38:308. doi: 10.11604/pamj.2021.38.308.26014. eCollection 2021. Pan Afr Med J. 2021. PMID: 34178226 Free PMC article.
-
The Vaginal Microbiome and its Potential to Impact Efficacy of HIV Pre-exposure Prophylaxis for Women.Curr HIV/AIDS Rep. 2017 Oct;14(5):153-160. doi: 10.1007/s11904-017-0362-z. Curr HIV/AIDS Rep. 2017. PMID: 28812207 Free PMC article. Review.
References
-
- Zhang C, McMahon J, Fiscella K, Przybyla S, Braksmajer A, LeBlanc N, et al. HIV Pre-Exposure Prophylaxis Implementation Cascade Among Health Care Professionals in the United States: Implications from a Systematic Review and Meta-Analysis. AIDS Patient Care STDs. 2019;33:507–27. 10.1089/apc.2019.0119 - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous